TKTakafumi Kohama

Takafumi Kohama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takafumi Kohama has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 August 2007
      • Vol. 52  (8) , 703-8

    Effect of French maritime pine bark extract on endometriosis as compared with leuprorelin acetate.

    by Takafumi Kohama, Kotaro Herai, Masaki Inoue

    To clarify the effect of Pycnogenol (Horphag Research, Geneva, Switzerland), French maritime pine bark extract, on endometriosis. Fifty-eight women were included in this study. They were operated on conservatively for endometriosis and surgically diagnosed with the condition. All patients were followed at 4, 12, 24 and 48 weeks after starting treatment to check for endometriosis signs and symptoms, including changes in CA-125 and estrogen levels (E2). Thirty-two patients in the Pycnogenol treatment group took 60 mg Pycnogenol orally a day for 48 weeks. The 26 patients who received gonadotropin-releasing hormone agonist (Gn-RHa) were treated in the standard way. Treatment with Pycnogenol slowly but steadily reduced the symptom scores. Treatment with Gn-RHa reduced the scores more efficiently; however, 24 weeks after the end of treatment, the scores suggested a recurrence of signs. No influence of treatment on menstrual cycles or E2 was observed in the Pycnogenol group. CA-125 decreased in both treatment groups. Patients with smaller endometriomas responded better to treatment as compared to patients with larger endometriomas. In the Gn-RHa group, the lowering of CA-125 concentrations was far more pronounced; however, a clear rebound effect was observed. Pycnogenol is a therapeutic alternative to Gn-RHa in the treatment of endometriosis.


  • Pycnogenol® alleviates pain associated with pregnancy

    by Takafumi Kohama, Masaki Inoue

    The effect of Pycnogenol® was studied in women in the third trimester of pregnancy, complaining of lower back pain, hip joint pain, pelvic pain (pain in the inguinal region), pain due to varices or calf cramps. The women were supplemented with Pycnogenol® at a dose of 30 mg/day without any other therapy. Alleviation of pain was evaluated by pain scores until delivery. A significant reduction of pain could be obtained compared with the control group, where no decrease in pain scores in any symptoms was reported. No unwanted effects were observed in the Pycnogenol® group. These results indicate the potential of Pycnogenol® to reduce pain associated with pregnancy. Copyright © 2006 John Wiley & Sons, Ltd.


    • 1 October 2004
      • Vol. 49  (10) , 828-32

    Analgesic efficacy of French maritime pine bark extract in dysmenorrhea: an open clinical trial.

    by Takafumi Kohama, Nobutaka Suzuki, Satoshi Ohno, Masaki Inoue

    To clarify the effect of Pycnogenol (Horphag Research, Switzerland), French maritime pine bark extract, on menstrual pain. We treated 47 patients with menstrual pain, aged 21-45 years, with Pycnogenol at 30 mg (2 capsules) orally twice a dysmenorrl day. The administration of Pycnogenol began on the eighth day of the first menstrual cycle and continued until the seventh day of the third menstrual cycle. Improvement was evaluated by measuring scores of symptoms during the first and second, and first and third menstrual cycle using the Wilcoxon rank sum test. Treatment with Pycnogenol lowered the pain scores for abdominal pain significantly (p < 0.05) as compared to pretreatment values. Pain relief in the second cycle of treatment was better as compared to the first cycle of treatment, as indicated by a higher level of significance (p < 0.01) and lower median pain score. The number of days with abdominal pain showed a trend toward fewer days with pain; however, the difference failed to reach significance. Relief of back pain was not that pronounced during the first cycle treated with Pycnogenol; the pain scores were not significantly different from those in the pretreatment period. However, continuation of treatment during the second cycle produced significant pain relief (p < 0.01). The number of days with back pain decreased. The number of days with pain was significantly lower (p < 0.01) in the second cycle of treatment with Pycnogenol. Pycnogenol has a potential analgesic effect on menstrual pain.